Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1. Pediatr Blood Cancer 2014 Sep;61(9):1701-3

Date

03/29/2014

Pubmed ID

24668947

DOI

10.1002/pbc.25040

Scopus ID

2-s2.0-84904420991   2 Citations

Abstract

Survival following childhood neuroblastoma is improving with low rates of secondary myeloid neoplasms. We describe a 13-month-old male with intermediate risk neuroblastoma who developed an isolated scalp therapy-related myeloid sarcoma (t-MS). Developmental delays and two distinct malignancies prompted constitutional evaluation. Chromosomal microarray identified a 7.3 Mb deletion of 9q22.32 to 9q31.1. He remains in remission 11 months following hematopoietic cell transplant. Unusual presentations of rare diseases necessitate a multidisciplinary approach and adaptation of standardized protocols to accommodate increased risks imposed by genetic variants.

Author List

Brickler MM, Basel DG, Gheorghe G, Margolis DM, Kelly ME, Ehrhardt MJ

Authors

Donald Basel MD Chief, Professor in the Pediatrics department at Medical College of Wisconsin
Molly Brickler NP Nurse Practitioner in the Pediatrics department at Medical College of Wisconsin
David A. Margolis MD Interim Chair, Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Chromosome Deletion
Chromosomes, Human, Pair 9
Combined Modality Therapy
Developmental Disabilities
Graft vs Host Disease
Humans
Infant
Male
Neoplasms, Second Primary
Neuroblastoma
Prognosis
Sarcoma, Myeloid
Secondary Prevention